Sponsors
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced February 7, 2025 by David Schweikert · Last progress February 7, 2025
Requires the Department of Health and Human Services to develop drug adherence guidelines that aim for 90% patient adherence for all Medicare Part B and Part D drugs. The guidelines must incorporate artificial intelligence and machine learning and, when practicable, encourage use of generics and biosimilars. The text sets targets and technology requirements but does not provide funding, deadlines, enforcement tools, or details on how adherence will be measured or promoted.
The bill seeks to boost Medicare medication adherence and lower drug costs by requiring AI/ML tools and promoting generics/biosimilars, but its unfunded, deadline-free mandate plus privacy, bias, and clinical-disruption risks mean benefits may not materialize and could create new harms without stronger implementation safeguards.
Medicare beneficiaries (and patients with chronic conditions) would receive AI/ML-driven adherence support for Part B and D drugs, increasing medication-taking and likely reducing hospitalizations and improving treatment effectiveness.
Medicare beneficiaries could pay lower drug costs because the bill promotes greater use of generics and biosimilars, enabling savings when patients switch from higher‑priced brand products.
Hospitals and health systems may gain efficiency from mandated AI/ML tools (personalized reminders and risk prediction), helping target interventions and potentially reducing provider workload over time.
Medicare beneficiaries, taxpayers, and providers may not realize promised benefits because the requirement is unfunded, lacks deadlines, and sets an ambitious 90% adherence target across Part B and D drugs, creating administrative burden with no clear enforcement or support.
Medicare beneficiaries and people with disabilities face increased privacy and algorithmic-bias risks from a mandated AI/ML requirement if the bill does not specify data-protection, transparency, or fairness safeguards.
Patients with chronic conditions (including many Medicare beneficiaries) could experience clinical disruption or reduced treatment effectiveness if pressure to switch to generics/biosimilars causes clinicians to change stable medication regimens.